UniversalDX funding news – Seville-based UniversalDX Raises €20 Million Loan from the European Investment Bank (EIB)

The EIB financing will support the expansion of Universal Dx’s most advanced product, Signal-C® for Colorectal Cancer Screening and the development of other pipeline products: Signal-Li and Signal-Lu for Liver and Lung cancer respectively.

Read also - Fund F funding news – Vienna-based Fund F Closes First Fund at €28Million

The loan will also support Universal DX international expansion plan, including advancing a large clinical trial in the US for FDA approval and reimbursement. The Sevilla-based startup is a MedTech pioneer.

Their technology is based on a proprietary, innovative platform encompassing a Next-Generation-Sequencing Assay, measuring Universal DX proprietary methylation, fragmentation, and microbiome biomarkers, and detecting the signal of the biomarker panel patterns with state-of-the-art Machine Learning-based bioinformatic solutions and algorithms.

EIB Director of Equity, Growth Capital and Project Finance Alessandro Izzo said, “We are delighted to join forces with Universal DX to advance the fight against cancer and more specifically the early detection of the illness to improve survival rate. This financing agreement is one more example of how the EIB is helping innovative European startups developing breakthrough medical solutions and supporting the European MedTech industry,”.

The EIB loan is guaranteed by InvestEU, the flagship EU programme to mobilize over €372 billion of additional public and private sector investment to support EU policy goals from 2021 to 2027. The project contributes to Europe’s Beating Cancer Plan and the EIB Group strategic priority of accelerating digitalisation and technological innovation.

Juan Martinez-Barea, Founder and Chairman of Universal DX said, “Our mission is to create a future where cancer is curable. With the transformative power of our technology, we are taking bold steps to turn this vision into reality. We are deeply inspired by the support of the EIB, which will enable us to contribute to the European Plan to Fight Cancer and to bring our revolutionary blood tests for early cancer detection to both European and U.S. markets.”

The investments associated to the project will generate cutting edge scientific knowledge and retaining European scientific acumen. The project will also contribute to Europe’s competitiveness boosting the innovative capacity of European based life science industries and businesses.

About UniversalDX

Universal DX is a biotech company headquartered in Spain with its US office in Dallas (Texas). Its mission is to transform cancer into a curable disease by detecting it early. Utilizing multi-omics, computational biology, and AI tools, UDX is deciphering the unique cfDNA sequences that capture cancer’s earliest signals. UDX’s most advanced assay is for colorectal cancer screening with high accuracy for pre-cancer and cancers.